Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Top Cited Papers
Open Access
- 1 August 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 15 (8) , 709-716
- https://doi.org/10.1016/s0895-7061(02)02957-6
Abstract
Background:. Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficaciouKeywords
This publication has 10 references indexed in Scilit:
- Mineralocorticoid receptor antagonists: The evolution of utility and pharmacologyKidney International, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive RatsHypertension, 1998
- Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failureJournal of Cardiac Failure, 1996
- Aldosterone and antialdosterone therapy in congestive heart failureThe American Journal of Cardiology, 1993
- Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.Circulation, 1991
- Efficacy and tolerance of spironolactone in essential hypertensionThe American Journal of Cardiology, 1987
- The tissue effects of mineralocorticoidsThe American Journal of Medicine, 1972
- Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animalEuropean Journal of Pharmacology, 1972
- Angiotensin II Vascular Receptors: Their Avidity in Relationship to Sodium Balance, the Autonomic Nervous System, and HypertensionJournal of Clinical Investigation, 1972